Alzhemier's disease - Pathophysiology and treatment

International Journal of Pharma and Bio Sciences

Volumn 1, Issue 2, 2010, Pages

  Shaik, Asma Shaheda ^a   Elaya Raja, A ^a   Vijayalakshmi, M ^b   Devalarao, G ^a  

^a KVSR SIDDHARTHA COLLEGE OF PHARMACEUTICAL SCIENCES   (India)

^b ACHARYA NAGARJUNA UNIVERSITY   (India)

Author keywords

Alzheimer; Dementia; Diagnosis; Pathology; Therapy

Indexed keywords

ACETYLCHOLINE; ALZHEIMER DISEASE VACCINE; AMYLOID PRECURSOR PROTEIN; ANTIOXIDANT; CHOLINERGIC RECEPTOR; CHOLINESTERASE INHIBITOR; ESTROGEN; MEMANTINE; RALOXIFENE; TAU PROTEIN;

AGITATION; ALZHEIMER DISEASE; ANXIETY DISORDER; AUTOIMMUNITY; BEHAVIOR DISORDER; BIOCHEMICAL COMPOSITION; CAREGIVER SUPPORT; DEMENTIA; DEPRESSION; DIAGNOSTIC IMAGING; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG HALF LIFE; ESTROGEN THERAPY; GENETIC ASSOCIATION; HUMAN; MEDICAL HISTORY; NEUROLOGIC EXAMINATION; NEUROPATHOLOGY; PHYSICAL EXAMINATION; PSYCHOSIS; RESTLESS LEGS SYNDROME; REVIEW; RISK FACTOR; RISK REDUCTION; SLEEP DISORDER; SLOW VIRUS DISEASE; STEM CELL TRANSPLANTATION; VASCULAR DISEASE;

EID: 84455205246     PISSN: None     EISSN: 09756299     Source Type: Journal    
DOI: None     Document Type: Review

References (55)

1. Harrison TR and Peterdsdoff RG. Harrison's principles of Internal Medicine. MC Graw Hill Publishers, London. Vol-II. 2008: 2539.
2. th edn; 927.
3. Knopman DS et al., Incidence and causes of nondegenerative nonvascular dementia: A population based study. Arch Neurol. 2006: 63; 218.
4. st edn; 155.
5. Cummings JL. Dementia. In: The failing brain. Lancet. 1995: 345; 1481-1484.
6. Gooch MD and Stennett DJ. Molecular basis of Alzheimer's disease. Am J Health-Syst Pharm. 1996: 53; 1545-1547.
7. www.yourtotal health.com-page 1-4.
8. www.neurologychannel.com/Alzheimer/index.5HTML
9. www.ALZinfo.org/pp1-4.
10. st edn.1998: 293.
11. th edn; 513-514.
12. st edn; 282.
13. Van Oijen M et al. Artherosclerosis and risk for dementia. Ann Neurol. 2007:61; 403.
14. www.encyclopedia.org/Alzheimer_disease.5-6pdfform.
15. www.wikipedia.org/wiki/Alzheimer_disease.1-4DOCXform.
16. Lewis DA and Bloom Fe. "Clinical Perspectives on neuropeptides" . Annu Rev Med, 1983: 23; 143.
17. Johnston MV. Cognitive disorders. In: Principles of drug therapy in Neurology. F.A.Davis Publications, Philadelphia, 1992: 226-267.
18. Perry EK. The cholinergic hypothesis-ten years on. Brit Med Bul, 1986: 42; 63-69.
19. th edition, 2005: 87; 241-242
20. Yankner BA, Duffy LK and Kirschner DA. Neurotrophic and Neurotoxic effects of amyloid β protein: reversal by tachykinin neuropeptides, Science, 1990: 250&279.
21. Arnold SE, et al. The topographical and neuro anatomical distribution of neurofibrillary tangles and neuritic plaques in the cerebral cortex of patients with Alzheimer's disease. Cereb. Cortex, 1991:1; 103-116.
22. Arrigada PV, et al. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurol. 1992: 42; 631-639.
23. Braak H and Braak E. Pathology of Alzheimer's disease. In: Neurodegenerative diseases.W.B. Saunders Publications, Philadelphia. 1994: 585-614.
24. Small GW et al. PET of brain amyloid and tau in mild cognitive impairment. N Engl J Med. 2007: 355; 2652.
25. www.medicalnewstoday.com/articles/9170.php
26. www.wikipedia.org/wiki/Alzheimer_disease.8-10pdf form
27. Martindale-The complete drug Reference. British Pharmaceutical Press. In: Parasympathomimetics. 1412.
28. www.alz.org/braintou1asp.HTML
29. www.alz.org/braintou2asp.HTML
30. www.alz.org/braintou3asp.HTML
31. www.alz.org/braintou4asp.HTML
32. www.alz.org/braintou5asp.HTML
33. www.nia.nih.gov/alzheimer'sdisease1HTML
34. www.nia.nih.gov/alzheimer'sdisease2HTML
35. www.alzheimer's.about.com-diagnosisindex.5html
36. www.ahaf.org/Alzheimer's.com.pp1-4.
37. Gottlieb GL and Kumar A. Conventional pharmacologic treatment for patients with Alzheimer's disease. Neurol.1993: 43(suppl 4); S56.
38. Arrigada PV et al. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurol. 1992: 42; 631-639.
39. Culter NR and Sramek JJ. Muscarinic M1 receptor agonists-potential in the treatment of Alzheimer's disease. CNS Drugs. 1995: 3; 467-469.
40. Eagger SA, et al. Tacrine in Alzheimer's disease. Lancet. 1991:337; 989-992.
41. Knapp MJ, et al. A 30 week randomized controlled trial of high dose tacrine in Patients of Alzheimer's disease. JAMA. 1994: 271; 985-987.
42. Levy R. Tacrine and Lecithin in Alzheimer's disease. Br.Med.J. 1990: 300; 939- 940.
43. Summers WK, et al. Tacrine as a treatment for Alzheimer's dementia. N Engl J Med. 1991: 324; 352.
44. Barar FSK. In: Essentials of Pharmacotherapeutics. S.Chand & Company, New Delhi. 2000: 164-169.
45. th edn; 78.
46. Schneider LS. Clinical pharmacology of amino acridines in Alzheimer's disease.Neurol. 1993: 43(suppl 4); S64.
47. National Institute for Clinical Excellence. Guidance on the use of donepezil, rivastigmine and galantamine for the treatment of Alzheimer's disease. (www.nice.org.uk/pdf/ALZHEIMER_full_guidance.pdf.) Issued 20.11.2001.
48. rd edn;100-102.
49. Sano M et al. A controlled trial of seligiline, α-tocopherol or both as treatment for Alzheimer's disease. N Engl J Med. 1997; 36:1216-1222.
50. Tariot PN et al, L-phrenyl in Alzheimer's disease. Arch Gen psychiatry. 1987: 44;418.
51. Thompson TL, Morgan MG and Nies AS. Psychotropic drug use in the elderly. (2 parts). N Engl J Med. 1983: 308; 134 & 194.
52. www.aarp.org/health/conditions/articles/harvard_a guide-to-alzheimer-s-disease_9.html
53. www.yourtotalhealth.com/html. pp 1-5.
54. A. Elayaraja et al. Nootropic activity of Ethanolic extrat of Acorus calamus Linn. Drug Lines. 10 (1&2), July 2007 - June 2008, 32-35.
55. R.Lakshmipathy. Health. In: Diet for human brain. 2010. 88(02). 21.